Does Adjunctive Tigecycline Improve Outcomes in Severe-Complicated, Nonoperative Infection?

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2017 May 9

PMID 28480257

Citations 8

Authors

Mary T LaSalvia

Westyn Branch-Elliman

Graham M Snyder

Monica V Mahoney

Carolyn D Alonso

Howard S Gold

Sharon B Wright

Affiliations

Soon will be listed here.

Abstract

Severe infection is associated with a high rate of mortality; however, the optimal treatment for severe- complicated infection remains uncertain for patients who are not candidates for surgical intervention. Thus, we sought to evaluate the benefit of adjunctive tigecycline in this patient population using a retrospective cohort adjusted for propensity to receive tigecycline. We found that patients who received tigecycline had similar outcomes to those who did not, although the small sample size limited power to adjust for comorbidities and severity of illness.

Citing Articles

Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.

Bishop E, Tiruvoipati R J Antimicrob Chemother. 2022; 78(1):21-30.

PMID: 36441203 PMC: 9780550. DOI: 10.1093/jac/dkac404.

Impact of Tigecycline on C. difficile Outcomes: Case Series and Propensity-Matched Retrospective Study.

Phillips E, Warren C, Ma J, Madden G Antimicrob Agents Chemother. 2022; 66(6):e0000122.

PMID: 35647645 PMC: 9211400. DOI: 10.1128/aac.00001-22.

South African Society of Clinical Microbiology infection diagnosis, management and infection prevention and control guideline.

Nana T, Moore C, Boyles T, Brink A, Cleghorn J, Devenish L S Afr J Infect Dis. 2021; 35(1):219.

PMID: 34485483 PMC: 8378053. DOI: 10.4102/sajid.v35i1.219.

Clostridioides difficile associated peritonitis in peritoneal dialysis patients - a case series based review of an under-recognized entity with therapeutic challenges.

Shah K, Cherabuddi K, Pressly K, Wright K, Shukla A BMC Nephrol. 2020; 21(1):76.

PMID: 32131755 PMC: 7055046. DOI: 10.1186/s12882-020-01734-8.

Management of colitis: insights for the gastroenterologist.

Saha S, Khanna S Therap Adv Gastroenterol. 2019; 12:1756284819847651.

PMID: 31105766 PMC: 6505238. DOI: 10.1177/1756284819847651.

References

Rieg S, Kupper M . Infectious diseases consultations can make the difference: a brief review and a plea for more infectious diseases specialists in Germany. Infection. 2016; 44(2):159-66. DOI: 10.1007/s15010-016-0883-1. View

Akerlund T, Svenungsson B, Lagergren A, Burman L . Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol. 2006; 44(2):353-8. PMC: 1392646. DOI: 10.1128/JCM.44.2.353-358.2006. View

Navalkele B, Lerner S . Intravenous Tigecycline Facilitates Cure of Severe Clostridium difficile Infection (CDI) After Failure of Standard Therapy: A Case Report and Literature Review of Tigecycline Use in CDI. Open Forum Infect Dis. 2016; 3(2):ofw094. PMC: 4943546. DOI: 10.1093/ofid/ofw094. View

Di X, Bai N, Zhang X, Liu B, Ni W, Wang J . A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis. 2015; 19(4):339-49. PMC: 9427463. DOI: 10.1016/j.bjid.2015.03.006. View

Neal M, Alverdy J, Hall D, Simmons R, Zuckerbraun B . Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011; 254(3):423-7. DOI: 10.1097/SLA.0b013e31822ade48. View

Johnson S, Louie T, Gerding D, Cornely O, Chasan-Taber S, Fitts D . Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014; 59(3):345-54. DOI: 10.1093/cid/ciu313. View

Jenkins T, Price C, Sabel A, Mehler P, Burman W . Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46(7):1000-8. DOI: 10.1086/529190. View

Walk S, Micic D, Jain R, Lo E, Trivedi I, Liu E . Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012; 55(12):1661-8. PMC: 3501335. DOI: 10.1093/cid/cis786. View

Thomas A, Khan F, Uddin N, Wallace M . Tigecycline for severe Clostridium difficile infection. Int J Infect Dis. 2014; 26:171-2. DOI: 10.1016/j.ijid.2014.04.025. View

10.

Smith K, Gould K, Ramage G, Gemmell C, Hinds J, Lang S . Influence of tigecycline on expression of virulence factors in biofilm-associated cells of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009; 54(1):380-7. PMC: 2798542. DOI: 10.1128/AAC.00155-09. View

11.

Koss K, Clark M, Sanders D, Morton D, Keighley M, Goh J . The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006; 8(2):149-54. DOI: 10.1111/j.1463-1318.2005.00876.x. View

12.

Britt N, Steed M, Potter E, Clough L . Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection. Infect Dis Ther. 2014; 3(2):321-31. PMC: 4269622. DOI: 10.1007/s40121-014-0050-x. View

13.

Hung Y, Lee J, Lin H, Liu H, Wu Y, Tsai P . Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection. Antibiotics (Basel). 2016; 4(2):216-29. PMC: 4790331. DOI: 10.3390/antibiotics4020216. View

14.

Zar F, Bakkanagari S, Moorthi K, Davis M . A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45(3):302-7. DOI: 10.1086/519265. View

15.

Gergely Szabo B, Kadar B, Szidonia Lenart K, Dezsenyi B, Kunovszki P, Fried K . Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. Clin Microbiol Infect. 2016; 22(12):990-995. DOI: 10.1016/j.cmi.2016.08.017. View

16.

Aldape M, Heeney D, Bryant A, Stevens D . Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother. 2014; 70(1):153-9. PMC: 4267498. DOI: 10.1093/jac/dku325. View

17.

Herpers B, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam H, Hornef M . Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis. 2009; 48(12):1732-5. DOI: 10.1086/599224. View

18.

Venugopal A, Johnson S . Current state of Clostridium difficile treatment options. Clin Infect Dis. 2012; 55 Suppl 2:S71-6. PMC: 3388023. DOI: 10.1093/cid/cis355. View

19.

Noren T, Alriksson I, Akerlund T, Burman L, Unemo M . In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect. 2009; 16(8):1104-10. DOI: 10.1111/j.1469-0691.2009.03048.x. View

20.

Kim H, Zhang Q, Sun X, Beamer G, Wang Y, Tzipori S . Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother. 2014; 58(12):7560-4. PMC: 4249528. DOI: 10.1128/AAC.03447-14. View